Unknown

Dataset Information

Glioblastoma update: molecular biology, diagnosis, treatment, response assessment, and translational clinical trials.


ABSTRACT: This is an exciting time in neuro-oncology. Discoveries elucidating the molecular mechanisms of oncogenesis and the molecular subtypes of glioblastoma multiforme (GBM) have led to new diagnostic and classification schemes with more prognostic power than histology alone. Molecular profiling has become part of the standard neuropathological evaluation of GBM. Chemoradiation followed by adjuvant temozolomide remains the standard therapy for newly diagnosed GBM, but survival remains unsatisfactory. Patients with recurrent GBM continue to have a dismal prognosis, but neuro-oncology centers with active clinical trial programs are seeing a small but increasing cadre of patients with longer survival. Molecularly targeted therapeutics, personalized therapy based on molecular profiling of individual

SUBMITTER: Lieberman F 

PROVIDER: S-EPMC5658706 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature